Home > Boards > US OTC > Biotechs > Vitro Diagnostics, Inc. (VODG)

Have you reduced any of your position yet?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Potse Member Profile
 
Followed By 34
Posts 496
Boards Moderated 0
Alias Born 03/19/09
160x600 placeholder
Potse   Friday, 03/08/19 07:08:05 AM
Re: JonesBur post# 2292
Post # of 2302 
Quote:
Have you reduced any of your position yet? Might be interesting to wait until after Q1 to see if they have any update/progress on officially reporting.



I sold some shares at 23 cents. I'm still expecting to see better selling opportunities in the coming weeks/months. The Q1 2019 press release could be one of those catalysts that moves the stock.

Regarding the filing delinquency: My concerns about the stock risk started increasing significantly back in December when the auditor resigned. As far as I am aware, the company has not yet hired a new firm. That, combined with the language/tone of the delinquency comments in the last press release, leads me to assume that VODG is not planning to cure the delinquency any time soon. So at this point, I think it is reasonable to believe that the filing delinquency risk will remain an overhang on the stock for a considerable amount of time.

From a business operations standpoint, there is a lot to be extremely excited about here. The upcoming doubling of the laboratory/production capacity, and the expectation that revenue from other foreign clinics will begin coming online later in fiscal 2019, all bodes well for the future of VODG.

I really like what I am seeing regarding this cosmetic product partnership that VODG has with Jack Zamora. A lot of investors may be overlooking how potentially huge this could become for VODG. If you go back and look at the numbers/language in the last two financial results press releases, you will notice that this cosmetic product began "early" or "initial" testing during Q4 2018. During this testing phase, it produced more than $100k in revenue for VODG (more than 19% of VODG's total 2018 revenue). Company guidance for this product is more than $300K for fiscal 2019.

Jack Zamora has significant connections/clout in the cosmetic surgery industry. If you monitor Zamora's personal/business social media accounts over the last couple/few months, I think it is pretty clear that he intends to heavily promote/push his Limitless MD procedure and the use of this cosmetic product in his associated clinics and industry-wide.

Kyma Anti-aging Center in Massachusetts is one of the clinics he is closely associated with. The picture of Zamora holding a vial of the cosmetic serum was taken in late January 2019 when he went to Kyma to teach the staff how to use the product......

https://www.kymaantiaging.com/limitlessmd-procedure

https://www.kymaantiaging.com/umbilical-cord-stem-cell

https://www.instagram.com/p/BuiNIjdjGKC/

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist